Loading...
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lu...
Na minha lista:
| Udgivet i: | Intern Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
The Japanese Society of Internal Medicine
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635316/ https://ncbi.nlm.nih.gov/pubmed/28794362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.8312-16 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|